Headquarters: Cambridge, Massachusetts, USA
Founded: 2016
Parent Company: Bayer AG (acquired 2019)
Pipeline Focus: Cell therapy for Parkinson's disease and other neurological disorders
BlueRock Therapeutics is a clinical-stage biotechnology company pioneering cell-based regenerative therapies for neurological diseases. The company's lead candidate, bemdaneprocel (BRII-001), is an investigational dopamine neuron replacement therapy for Parkinson's disease that has demonstrated promising results in Phase I clinical trials[1].
Founded in 2016 as a venture between Bayer AG and Versant Ventures, BlueRock leverages its proprietary pluripotent stem cell platform to generate specialized cell products for tissue repair and regeneration. The company's mission focuses on developing curative cell therapies that address the underlying neurodegeneration in Parkinson's disease rather than merely managing symptoms[2].
Mechanism: Dopamine neuron replacement therapy using human embryonic stem cell (hESC)-derived dopaminergic progenitor cells
Stage: Phase III (exPDite-2)
Status: Enrolling
Bemdaneprocel (also known as exPDite-2 in the Phase III trial) is an investigational cryopreserved, off-the-shelf dopaminergic neuron progenitor cell product derived from human embryonic stem cells. The therapy aims to replace the dopamine-producing neurons lost in Parkinson's disease by transplanting progenitor cells into the patient's brain, where they mature into functional dopamine neurons[1:1][3].
Clinical Development:
Key Findings from Phase I (18-24 month data):
The Phase I data demonstrate safety and support advancement to definitive clinical studies for bemdaneprocel as a disease-modifying treatment for Parkinson's disease. The registrational Phase III trial (exPDite-2) is actively enrolling patients with primary completion expected in 2027-2028.
BlueRock's proprietary platform enables:
The platform builds on foundational research in human embryonic stem cell differentiation toward midbrain dopaminergic neurons, building on protocols developed by Studer and colleagues[5][6].
The company's approach addresses the root cause of Parkinson's disease by:
Following the acquisition, BlueRock operates as a wholly-owned subsidiary of Bayer AG, maintaining its research operations in Cambridge, Massachusetts. The partnership provides significant resources for clinical development and leverages Bayer's global manufacturing and commercialization capabilities[9].
BlueRock represents Bayer's flagship cell therapy asset in the neuroscience space. The company positions itself at the forefront of regenerative medicine, with potential applications beyond Parkinson's disease to other neurological conditions characterized by neuronal loss.
BlueRock's leadership combines biotech entrepreneurship with deep expertise in stem cell biology and neurosurgery:
The landmark Phase I trial results were published in Nature, demonstrating the safety and preliminary efficacy of bemdaneprocel[1:4]:
"These data demonstrate safety and support future definitive clinical studies."
The trial represents a significant milestone in cell therapy for Parkinson's disease, establishing the foundation for future clinical development of dopamine neuron replacement approaches.
BlueRock continues to advance bemdaneprocel through clinical development, with plans for expanded Phase II trials with larger patient cohorts, longer-term follow-up to assess durability of benefits, and optimization of delivery and immunosuppression protocols.
BlueRock's R&D strategy emphasizes cell replacement therapies that replace lost neurons, disease modification targeting underlying disease mechanisms, platform expansion applying cell therapy platform to additional neurological conditions, and manufacturing innovation improving scalable cell production methods[10].
BlueRock competes with other cell therapy approaches for Parkinson's disease, including International Stem Cell Corporation developing neural stem cell therapies, Aspen Neuroscience working on autologous neuron replacement, Kyowa Kirin supporting research in dopamine neuron transplantation, and Summit Biomedical developing small molecule approaches. BlueRock's differentiation lies in its use of hESC-derived progenitors with demonstrated graft survival and functional integration in human patients.
Tabar V, et al. Bemdaneprocel for Parkinson's disease. Nature. 2025. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Kirkeby A, et al. Challenges in upscaling human stem cell-derived neuronal cell replacement therapies. Stem Cell Reports. 2024. ↩︎
Parmar M, et al. Dopamine neuron replacement: toward clinical translation. Nature Reviews Neurology. 2024. ↩︎
Kriks S, et al. Derivation of midbrain dopamine neurons from embryonic stem cells. Nature. 2011. ↩︎
Studer L. Derivation of dopamine neurons from pluripotent stem cells. Progress in Brain Research. 2022. ↩︎
Grealish S, et al. Cell therapy for Parkinson's disease: a stepwise approach. Brain. 2023. ↩︎
Barker RA, et al. Designing stem-cell-based dopamine cell replacement trials for Parkinson's disease. Nature Medicine. 2023. ↩︎
Tomishima M, et al. Manufacturing of pluripotent stem cell-derived dopamine neurons for clinical application. Cell Stem Cell. 2024. ↩︎